Assessment of proliferating cell nuclear antigen and its relationship with proinflammatory cytokines and parameters of disease activity in multiple myeloma patients

European Journal of Histochemistry

Volumn 55, Issue 3, 2011, Pages 115-118

  Tsirakis, G ^a   Pappa, C A ^b   Kaparou, M ^a   Katsomitrou, V ^a   Hatzivasili, A ^b   Alegakis, T ^c   Xekalou, A ^a   Stathopoulos, E N ^a   Alexandrakis, M G ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b Venizelion Hospital of Heraklion   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Interleukin 1 ; Interleukin 6; Interleukin 8; MIP 1 ; Multiple myeloma; Proliferating cell nuclear antigen

Indexed keywords

BETA 2 MICROGLOBULIN; CYCLINE; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN;

AGED; ARTICLE; BLOOD; CANCER STAGING; CELL PROLIFERATION; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1Β; MALE; METABOLISM; MIDDLE AGED; MIP-1Α; MULTIPLE MYELOMA; PATHOLOGY; PROLIFERATING CELL NUCLEAR ANTIGEN.;

INTERLEUKIN-1Β; INTERLEUKIN-6; INTERLEUKIN-8; MIP-1Α; MULTIPLE MYELOMA; PROLIFERATING CELL NUCLEAR ANTIGEN.;

AGED; BETA 2-MICROGLOBULIN; CELL PROLIFERATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN;

EID: 80052652545     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2011.e21     Document Type: Article

References (28)

1. Lauta VM. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003;97:2440-52.
2. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998;16:249-84.
3. Skopelitou A, Tselenis S, Theocharis S, Agnantis N, Tsenga A, Elemenoglou J, et al. Expression of proliferating cell nuclear antigen (PCNA) and nucleolar organizer regions (NORs) in multiple myeloma. Anticancer Res 1994;14:787-92.
4. Alexandrakis MG, Passam FH, Pappa CA, Dambaki C, Sfakiotaki G, Alegakis AK, et al. Expression of proliferating cell nuclear antigen (PCNA) in multiple myeloma: its relationship to bone marrow microvessel density and other factors of disease activity. Int J Immunopathol Pharmacol 2004;17:49-56.
5. Wilkins BS, Harris S, Waseem NH, Lane DP, Jones DB. A study of cell proliferation in formalin-fixed, wax-embedded bone marrow trephine biopsies using the monoclonal antibody PC10, reactive with proliferating cell nuclear antigen (PCNA). J Pathol 1992;166:45-52.
6. Zölzer F, Basu O, Devi PU, Mohanty SP, Streffer C. Chromatin-bound PCNA as Sphase marker in mononuclear blood cells of patients with acute lymphoblastic leukaemia or multiple myeloma. Cell Prolif 2010;43:579-83.
7. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA. Comparison of interleukin- 1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999;93:300-5.
8. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
9. Dinarello CA. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med 2011;269:16-28.
10. Kline M, Donovan K, Wellik L, Lust C, Jin W, Moon-Tasson L, et al. Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007;31:591-8.
11. Strieter RM, Polverini PJ, Arenberg DA, Walz A, Opdenakker G, Van Damme J, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol 1995;57:752-62.
12. Cook DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol 1996;59:61-6.
13. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-5.
14. Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer 2003;88:855-62.
15. Uneda S, Hata H, Matsuno F, Harada N, Mitsuya Y, Kawano F, et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003;120:53-5.
16. Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, et al. The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol 2010;38:860-7.
17. Suguro M, Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, et al. High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin- dexamethasone (VAD) salvage for refractory multiple myeloma. Am J Hematol 2000;65:132-5.
18. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol 2010;85:114-9.
19. Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003;82:19-23.
20. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36: 842-54.
21. Pappa C, Miyakis S, Tsirakis G, Sfiridaki A, Alegakis A, Kafousi M, Stathopoulos EN, Alexandrakis MG. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma. Cytokine 2007;37:171-5.
22. Xiong Y, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ, et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res 2006;26:83-95.
23. Donovan KA, Lacy MQ, Gertz MA, Lust JA. IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma. Leukemia 2002;16:382-5.
24. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001;250:91-104.
25. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 2001;12:375-91.
26. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-76.
27. Romagnani P, Lasagni L, Annunziato F, Serio M, Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004;25:201-9.
28. Pellegrino A, Ria R, Di Pietro G, Cirulli T, Surico G, Pennisi A, et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol 2005;129:248-56.